Skip to main content

Table 1 Inclusion criteria

From: Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

Patients fulfilling all of the following inclusion criteria may be enrolled in the study
Inclusion criteria:
· Histologically or cytologically confirmed and documented malignant pleural mesothelioma with pleural effusion,
· Male and Female patients 18 years to 75 years of age,
· Signed Informed Consent after being informed,
· Patients medically and/or functionally at screening not accessible for surgical treatment with planned third cycle of palliative chemotherapy in 21 days,
· Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x 109/L; absolute neutrophile count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L,
· Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times upper limit of normal (ULN)); bilirubin ≤ 1.5 x ULN,
· Renal: creatinine ≤ 2 mg/dL and creatinine clearance ≥ 45 mL/min,
· No concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents,
· The patient has received no major organ allograft,
· HIV-negative,
· HBV and HCV negative,
· No uncontrolled bleeding disorder,
· Patients of child-producing potential must agree to use contraception while enrolled in the study and for 24 months after the adoptive transfer.